INmune Bio (INMB) Q2 FY26 earnings call

INmune Bio Inc. advanced its late-stage platforms, Ebstracell and EXPRO, with significant regulatory and clinical milestones. Ebstracell is on track for UK MAA submission by end of Q3 or early Q4 2026, supported by manufacturing readiness and supply chain agreements. EXPRO's Phase 2 data and FDA Fast-Track designation strengthen its path forward, while the company focuses on disciplined execution and capital preservation to reach potential commercialization.